Point State Capital LP Gilead Sciences, Inc. Transaction History

Point State Capital LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $8.46 Million - $9.13 Million	-125,000 Reduced 67.57%	60,000 $4.19 Million
Q1 2021 May 14, 2021	BUY	$60.0 - $68.46 $5.76 Million - $6.58 Million	96,069 Added 108.03%	185,000 $12 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $364,316 - $415,121	6,431 Added 7.8%	88,931 $5.18 Million
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $18.9 Million - $23.8 Million	-304,817 Reduced 78.7%	82,500 $5.21 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $2.29 Million - $2.66 Million	31,646 Added 8.9%	387,317 $29.8 Million

Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $19.4 Million - $24.9 Million	310,455 Added 686.6%	355,671 $26.6 Million
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $2.79 Million - $3.06 Million	45,216 New	45,216 $2.94 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $74.5 Million - $86.9 Million	-1,148,301 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $83.6 Million - $102 Million	1,148,301 New	1,148,301 $86.6 Million

1,885

8.71M

8.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $85.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.